−$0.31 (0.98%) At close $31.33 · Today
☾After Hours −$0.06 (0.21%) Nov 3, 7:59 PM ET
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue EstimatesIDEAYA Biosciences reported a Q3 loss of $1.22 per share, beating the consensus estimate of $1.26 loss by 3.18%. The company posted revenues of $10.24 million, surpassing consensus by 14.69%, though this represents a significant decline from $207.83 million in the year-ago quarter. The stock has underperformed the S&P 500 by 18.7% year-to-date and carries a Zacks Rank #3 (Hold) rating.
Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?IDEAYA Biosciences is expected to report a quarterly loss of $1.26 per share with revenues of $8.93 million for Q3 2026, representing significant year-over-year declines. However, the company has a positive Earnings ESP of +1.50% combined with a Zacks Rank #3 (Hold), suggesting it will likely beat consensus EPS estimates. The company has only beaten estimates once in the last four quarters.
Zacks Investment Research
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineAcadia Pharmaceuticals is expected to report Q3 2026 earnings of $0.21 per share, representing a 19.2% year-over-year decline, despite revenues rising 20.2% to $334.87 million. With a negative Earnings ESP of -0.59% and Zacks Rank #3, the company is not considered a compelling earnings-beat candidate. However, Acadia has beaten consensus EPS estimates in 3 of the last 4 quarters, most recently delivering a +200% surprise.
Headlines open the publisher's site.
